GlassScriptPhysician profile
William B Robinson
NPI 1114962339
$7,298.09
in general payments reported to CMS, 2019-2025
47 companies · $68.81 in 2025
The $68.81 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,615 · 2020: $613 · 2021: $1,428 · 2022: $1,998 · 2023: $1,379 · 2024: $195 · 2025: $68.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,643.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $834.45 | 2019-2023 | Repatha, Otezla |
| Abbvie INC. | $630.25 | 2019-2023 | Vraylar, Linzess, Ubrelvy |
| Novo Nordisk INC | $602.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $556.07 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.11 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $416.92 | 2019-2024 | Airsupra |
| Astellas Pharma US INC | $390.26 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $343.34 | 2019-2023 | |
| Abbott Laboratories | $330.79 | 2022-2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $326.18 | 2021-2023 | |
| Lilly USA, LLC | $303.23 | 2019-2024 | Jardiance, Mounjaro |
| Sanofi-Aventis U.S. LLC | $222.35 | 2019-2022 | |
| Daiichi Sankyo INC. | $198.71 | 2019-2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $192.19 | 2021-2023 | Takhzyro |
| Janssen Pharmaceuticals, INC | $159.54 | 2019-2023 | Xarelto |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.